Related Experiment Videos
Pseudotumor cerebri in an infant after L-thyroxine therapy for transient neonatal hypothyroidism
S Raghavan1, J DiMartino-Nardi, P Saenger
1Department of Pediatrics, Monteflore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10467, USA.
Insights
Pseudotumor cerebri, a benign condition, can occur in infants treated with L-thyroxine for hypothyroidism. This case highlights a rare instance in an infant linked to maternal antibodies.
Area of Science:
- Pediatric Endocrinology
- Neurology
- Immunology
Background:
- Pseudotumor cerebri (PTC) is typically a benign intracranial hypertension disorder.
- PTC has been associated with hypothyroidism and L-thyroxine replacement therapy.
- Prior reports focused on peripubertal children (8-13 years).
Observation:
- This report details a rare case of PTC in an infant.
- The infant received L-thyroxine for transient neonatal hypothyroidism.
- The hypothyroidism stemmed from maternal thyroid-stimulating hormone receptor-blocking antibodies.
Findings:
- Development of pseudotumor cerebri in an infant treated with L-thyroxine.
- Establishes a link between L-thyroxine therapy for neonatal hypothyroidism and PTC in infants.
- Suggests maternal antibodies as a potential contributing factor.
Implications:
- Highlights the need for vigilance regarding PTC in infants on L-thyroxine therapy.
- Broadens the age spectrum for PTC associated with L-thyroxine to include infancy.
- May inform diagnostic and management strategies for neonatal hypothyroidism and associated complications.
Abstract:
Pseudotumor cerebri is generally a benign disorder. It has been reported to occur in hypothyroidism, particularly after the initiation of L-thyroxine replacement therapy. Previous case reports have involved children primarily in the peripubertal age range (approximately 8 to 13 years). We report here the development of pseudotumor cerebri in an infant who required treatment with L-thyroxine for transient neonatal hypothyroidism as a result of maternal thyroid-stimulating hormone receptor-blocking antibodies.